Business
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
Nes-Ziona, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the
About this update from Enlivex Ltd.
[{"type":"text","content":"Nes-Ziona, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering to certain institutional investors of 1,000,000 ordinary shares of the Company at a purchase price of $8.00 per share for aggregate gross proceeds of $8.0 million.\n H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.The Company intends to use the net proceeds from the offering for clinical, regulatory, manufacturing and research and development activities, potential acquisitions and in-licensing, as well as for working capital and other general corporate purposes. A shelf registration statement on Form F-3 (File No. 333-232009) relating to the ordinary shares offered in the registered direct offering was filed with the Securities and Exchange Commission (the “SEC”) on June 7, 2019 and declared effective by the SEC on June 21, 2019. The offering was made only by means of the written prospectus and prospectus supplement that form a part of such shelf registration statement. A final prospectus supplement related to the offering has been filed with the SEC and may be obtained for free by visiting EDGAR on the SEC website at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, or by calling (646) 975-6996 or by emailing [email protected]. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein or any other securities, nor shall there be any sale of the securities described herein or any other securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. ABOUT ENLIVEX Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve an out of control immune system (e.g. Cytokine Release Syndrome) and for which ther...